Shares of Cardio Diagnostics Holdings, Inc. (CDIO) are up 65% on Monday following the announcement of a groundbreaking study on the development and validation of PrecisionCHD, an innovative AI-guided integrated genetic-epigenetic test that can accurately detect coronary heart disease (CHD) through a simple blood draw. <\/p>\n
CDIO is trading on the Nasdaq at $1.64, up 65.65% or $0.65 per share. It has traded between $0.17 and $8.50 in the past 52-week period.<\/p>\n
The test’s validation was published in the Journal of the American Heart Association(JAHA), in an article titled “The Validation of an Integrated Genetic-Epigenetic Test for the Assessment of Coronary Heart Disease”.<\/p>\n
This achievement marks a significant leap in the diagnosis of CHD, as traditional diagnostic methods are often invasive, expose patients to ionizing radiation, and require specialized infrastructure, making them inaccessible to many.<\/p>\n
PrecisionCHD’s introduction now provides clinicians with a powerful, scalable, non-invasive alternative for detecting CHD. The test uses personalized genetic and epigenetic information and AI to sensitively detect the presence of CHD. <\/p>\n
It is the first integrated genetic-epigenetic test for CHD detection that uses the input from six methylation-sensitive digital PCR (MSdPCR) assessments to determine the presence or absence of CHD.<\/p>\n
With PrecisionCHD, patients in underserved areas will now have access to state-of-the-art cardiac assessments through a simple blood draw. The test’s ability to be administered in primary care or telemedicine settings significantly reduces the need for patients from rural communities to travel to distant specialized clinics. <\/p>\n